Cover Image
市場調查報告書

急性脊髓損傷:開發平台分析

Acute Spinal Cord Injury - Pipeline Review, H2 2015

出版商 Global Markets Direct 商品編碼 213133
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
急性脊髓損傷:開發平台分析 Acute Spinal Cord Injury - Pipeline Review, H2 2015
出版日期: 2015年08月26日 內容資訊: 英文 52 Pages
簡介

急性脊髓損傷 (SCI)是指脊髓因為跌打傷和局部斷裂造成的外傷。事故後脊髓損傷的緊急度症狀有背部劇痛、頭頸或背後感到壓迫感、身體某處麻痺、手或手指、腳尖失去知覺或感到刺痛、排尿、排便失控、難以平衡地走路、受傷後無法正常呼吸、頭頸與背姿勢怪異或無法彎曲。

本報告提供急性脊髓損傷的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃等相關資訊。以及最新的新聞和發表等資訊。

簡介

  • 調查範圍

急性脊髓損傷 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Acorda Therapeutics, Inc.
  • Kringle Pharma, Inc.
  • Neuralstem, Inc.
  • Neuronax SAS

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AC-105
  • BA-210
  • Cell Therapy for Spinal Cord Injury
  • KP-100IT
  • NSI-566
  • NX-210
  • Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury
  • Peptides to Inhibit Major Histocompatibility Complex Class I and II for Central Nervous System and Musculoskeletal Disorders
  • Stem Cell Therapy for Acute Spinal Cord Injury

最近的開發平台趨勢

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7016IDB

Summary

Global Markets Direct's, 'Acute Spinal Cord Injury - Pipeline Review, H2 2015', provides an overview of the Acute Spinal Cord Injury's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Spinal Cord Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Spinal Cord Injury and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Spinal Cord Injury
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Spinal Cord Injury and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Spinal Cord Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Spinal Cord Injury pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Spinal Cord Injury
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Spinal Cord Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Acute Spinal Cord Injury Overview
  • Therapeutics Development
    • Pipeline Products for Acute Spinal Cord Injury - Overview
    • Pipeline Products for Acute Spinal Cord Injury - Comparative Analysis
  • Acute Spinal Cord Injury - Therapeutics under Development by Companies
  • Acute Spinal Cord Injury - Therapeutics under Investigation by Universities/Institutes
  • Acute Spinal Cord Injury - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Acute Spinal Cord Injury - Products under Development by Companies
  • Acute Spinal Cord Injury - Products under Investigation by Universities/Institutes
  • Acute Spinal Cord Injury - Companies Involved in Therapeutics Development
    • Kringle Pharma, Inc.
    • Neuralstem, Inc.
    • Neuronax SAS
    • Vertex Pharmaceuticals Incorporated
  • Acute Spinal Cord Injury - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Cell Therapy for Spinal Cord Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KP-100IT - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NSI-566 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NX-210 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptides for Central Nervous System and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Stem Cell Therapy for Acute Spinal Cord Injury - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VX-210 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Acute Spinal Cord Injury - Recent Pipeline Updates
  • Acute Spinal Cord Injury - Dormant Projects
  • Acute Spinal Cord Injury - Discontinued Products
  • Acute Spinal Cord Injury - Product Development Milestones
    • Featured News & Press Releases
      • Nov 26, 2013: NX210 receives Orphan Drug Designation in Europe for the treatment of spinal cord injuries
      • Oct 15, 2012: Neuronax receives 600.000 euros from Oseo to support its NX210 Project
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Acute Spinal Cord Injury, H2 2015
  • Number of Products under Development for Acute Spinal Cord Injury - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Acute Spinal Cord Injury - Pipeline by Kringle Pharma, Inc., H2 2015
  • Acute Spinal Cord Injury - Pipeline by Neuralstem, Inc., H2 2015
  • Acute Spinal Cord Injury - Pipeline by Neuronax SAS, H2 2015
  • Acute Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Acute Spinal Cord Injury Therapeutics - Recent Pipeline Updates, H2 2015
  • Acute Spinal Cord Injury - Dormant Projects, H2 2015
  • Acute Spinal Cord Injury - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Acute Spinal Cord Injury, H2 2015
  • Number of Products under Development for Acute Spinal Cord Injury - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top